CAR T-cell therapies in GBM have been designed to target numerous tumor-specific antigens, such as epidermal growth factor receptor variant III (EGRFvIII) [10,11,12,13], interleukin13 receptor alpha 2 (IL13Rα2) [14,15,16,17,18], human epidermal growth factor receptor 2 (HER2) [19,20], B7-H3 (CD276) [21,22,23], disialoganglioside (GD-2) [24], and erythropoietin-producing hepatocellular carcinoma A 2 (EphA2) [25]. This evidence concerns the gene CD276 and neoplasm.